← Back to Search

Unknown

BGB-23339 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of study (up to 11 weeks)
Awards & highlights

Study Summary

This trial looks at how well a new drug works in Japanese and Caucasian people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of study (up to 11 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of study (up to 11 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with Adverse Events (AEs)
Secondary outcome measures
Apparent systemic clearance (CL/F) of BGB-23339
Apparent terminal elimination half-life (t½) of BGB-23339
Apparent volume of distribution (Vz/F) of BGB-23339
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part B: Caucasian cohortExperimental Treatment2 Interventions
One dose level of either BGB-23339 or placebo based on data collected in Part A.
Group II: Part A: Japanese cohortExperimental Treatment2 Interventions
Three ascending dose levels of either BGB-23339 or placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BGB-23339
2021
Completed Phase 1
~100
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

BeiGeneLead Sponsor
175 Previous Clinical Trials
28,814 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
2022. "Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05387668.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top